Oral Bioavailability of GS‑441524 Tablets

2026-09-15


Abstract

Oral bioavailability describes the fraction of an orally administered drug that successfully enters systemic circulation and achieves therapeutically active plasma concentration after gastrointestinal absorption. For GS‑441524, a nucleoside analogue antiviral drug widely used in feline infectious peritonitis (FIP) therapy, its oral bioavailability in cats is limited due to molecular hydrophilicity, gastrointestinal transporter metabolism and formulation differences. This explains why the labelled tablet weight may differ from the final effective systemic dose received by the cat. This article explains the core principle of oral absorption, factors affecting GS‑441524 bioavailability, and the clinical dosing logic for oral tablets.


1. Definition of Oral Bioavailability

Bioavailability (F, expressed as %) is the core pharmacokinetic parameter comparing the systemic drug exposure after oral administration versus intravenous injection. Intravenous injection delivers 100% of the drug directly into blood circulation (F=100%). For oral tablets, drug must go through tablet disintegration, dissolution in gastrointestinal fluid, intestinal membrane permeation, and first-pass hepatic metabolism. A portion of the drug is lost during this process, so F is always less than 100%.
Formula:
Bioavailability (F) = AUC(oral) / AUC(intravenous) ×100%
AUC = Area Under Curve, representing total systemic drug exposure over time.

2. Pharmacokinetic Characteristics of GS‑441524

GS‑441524 is a hydrophilic nucleoside analogue. It cannot freely diffuse across intestinal epithelial cell membranes and relies on nucleoside transporters (ENT1, ENT2, CNT3) for intestinal absorption. This property leads to moderate to low oral bioavailability across species, and significant inter‑species differences.
Preclinical studies show:
  • Monkeys: F≈8.3%
  • Mice: F≈39%
  • Dogs: F≈85%
  • In cats: The oral bioavailability of GS‑441524 varies significantly with formulation. Oral tablet formulations exhibit variable absorption, and the active plasma concentration obtained after oral administration is lower than subcutaneous injection.
For FIP treatment in cats, veterinarians calculate the target systemic effective dose based on plasma concentration requirement. When using oral tablets, veterinarians increase the tablet loading dose to compensate for low absorption. For example, a tablet marked 55 mg GS‑441524 may deliver an absorbed systemic effective dose equivalent to 40 mg, accounting for oral absorption loss.


3. Key Factors Affecting GS‑441524 Tablet Absorption

  1. Formulation Technology
    Raw GS‑441524 powder has poor water solubility. Tablet excipients, salt modification (hydrochloride / sulfate salt), disintegrants will directly affect dissolution rate. Salt-modified GS‑441524 can improve solubility and boost plasma concentration up to 3.8 times compared with raw GS‑441524.
  2. Gastrointestinal environment of cats
    Gastric emptying speed, intestinal pH, food intake will influence tablet disintegration and absorption. Feeding with food may alter absorption rate and peak plasma concentration.
  3. Transporter & first-pass metabolism
    GS‑441524 is a substrate of BCRP and MDR1 efflux transporters on intestinal wall. Part of dissolved drug is pumped back into intestinal lumen and cannot enter blood. Remaining absorbed drug undergoes partial hepatic first-pass metabolism before entering systemic circulation.
  4. Individual variation
    Age, weight, gastrointestinal health, inflammation status of the cat will cause individual differences in absorption efficiency.

4. Clinical Dosing Explanation for Oral Tablets

When veterinarians prescribe a dose of 15 mg/kg for FIP therapy, this value usually refers to the target effective systemic dose (the drug quantity that needs to reach blood circulation).
If using oral tablets with limited bioavailability, a higher nominal tablet mass must be administered to compensate for absorption loss. This is why the nominal mass written on the tablet can be higher than the final absorbed effective dose.
Important note: The conversion between tablet nominal content and absorbed effective dose is formulation-specific. Dose adjustment must be confirmed with your treating veterinarian before use.
References 

  1. Lee SR, et al. A dual-strategy approach to improve GS-441524 therapy in feline infectious peritonitis: salt engineering and orally disintegrating tablet development. Journal of Veterinary Pharmacology and Therapeutics.
  2. Coggins M, et al. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Journal of Veterinary Internal Medicine. PMC7117434
  3. Zhang C, et al. Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, a Potential Oral Drug Candidate. Frontiers in Pharmacology, 2022. PMC9424906
  4. Solikhah, et al. Review Article: Pharmacology GS-441524, Source, Pharmacodynamics, Pharmacokinetics, And Efficacy in Treatment of Feline Infectious Peritonitis. Journal of Respiratory and Virology Infections,2024
BACK